160
Participants
Start Date
September 30, 2025
Primary Completion Date
September 30, 2026
Study Completion Date
December 31, 2026
Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test
"Described in Arms section"
Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)
"Described in Arms section"
PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
Administered to patients randomized to Intervention group and with H. pylori clarithromycin-sensitive strain
PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days
Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-sensitive strain
Bismuth quadruple therapy (Pylera®) for 10 days
Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-resistant strain
Unilabs Portugal, Porto
Manuel Coelho da Rocha
OTHER